Cetrorelix
From Wikipedia, the free encyclopedia
 |
|
|
Cetrorelix
|
|
| Systematic (IUPAC) name | |
| Acetyl-D-3-(2´-naphtyl)-alanine- D-4-chlorophenylalanine-D-3-(3´-pyridyl)- alanine-L-serine-L-tyrosine-D-citruline-L- leucine-L-arginine-L-proline-D- alanine-amide | |
| Identifiers | |
| CAS number | |
| ATC code | H01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | ? |
| Mol. mass | 1431.06 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 85% |
| Protein binding | 86% |
| Metabolism | ? |
| Half life | 62.8 hours / 3mg single dose |
| Excretion | Liver |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) |
| Legal status | |
| Routes | Subcutaneous injection |
Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily or weekly subcutaneous injection.
Cetrorelix is marketed by Solvay Pharmaceuticals as Cetrotide.[1]
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
